<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Technetium Tc-99m succimer: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Technetium Tc-99m succimer: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Technetium Tc-99m succimer: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="17087" href="/d/html/17087.html" rel="external">see "Technetium Tc-99m succimer: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="138539" href="/d/html/138539.html" rel="external">see "Technetium Tc-99m succimer: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56629061"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Nephroscan</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F13210343"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Radiopharmaceutical</li></ul></div>
<div class="block doa drugH1Div" id="F13214966"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fda51a12-e386-416d-b60c-9fd041a5daa0">Renal imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal imaging: IV:</b> 2 to 6 mCi (74 to 222 MBq).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990869"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. <b>Note:</b> For patients with severely reduced eGFR, delaying imaging to between 6 to 24 hours after administration may improve image quality.</p></div>
<div class="block doha drugH1Div" id="F50988154"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F56670885"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; use with caution.</p></div>
<div class="block dop drugH1Div" id="F56678174"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="138539" href="/d/html/138539.html" rel="external">see "Technetium Tc-99m succimer: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fda51a12-e386-416d-b60c-9fd041a5daa0">Renal imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal imaging:</b> Infants, Children, and Adolescents: IV: 1.85 MBq/kg (0.05 mCi/kg); begin imaging 1 to 4 hours after administration.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F56678175"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; patients with severely reduced eGFR should have imaging delayed up to 6 to 24 hours to obtain satisfactory images.</p></div>
<div class="block dohp drugH1Div" id="F56678176"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F13214978"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F56670878"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F13210349"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity (eg, erythema, pruritus, rash, urticaria) occurring within 2 hours to several hours after administration has been reported. Appropriate medication and equipment should be readily available during and after administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Patients with renal disease may have delayed elimination, therefore decreasing quality of images; consider delaying imaging 6 to 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority. <b>Note:</b> Contents of kit are not radioactive; however, adequate shielding is required after addition of radioactive material.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Patients should be adequately hydrated prior to dosing; instruct patients to void frequently following administration to decrease radiation exposure to the bladder.</p></div>
<div class="block foc drugH1Div" id="F56629062"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Kit, Intravenous:</p>
<p style="text-indent:-2em;margin-left:4em;">Nephroscan: Succimer 1 mg per vial (5s) [to be combined with sodium pertechnetate Tc99m injection solution (not included)]</p></div>
<div class="block geq drugH1Div" id="F20452820"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block adm drugH1Div" id="F20223274"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV: </b>For IV administration only. Position patient in the prone or supine position; begin imaging 1 to 4 hours after administration. For patients with severely reduced eGFR, delaying imaging to between 6 to 24 hours after administration may improve image quality. Ensure adequate hydration prior to administration and encourage patient to drink fluids following administration. To minimize bladder exposure, patients should void frequently following administration.</p>
<p style="text-indent:0em;margin-top:2em;">Radiopharmaceutical; use appropriate precautions for handling and disposal.</p></div>
<div class="block admp drugH1Div" id="F56678177"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: Administer by slow IV injection. Radiopharmaceutical; use appropriate precautions for handling and disposal. Ensure adequate hydration prior to administration and encourage patient to drink fluids following administration. To minimize bladder exposure, patients should void frequently following administration.</p></div>
<div class="block use drugH1Div" id="F13210344"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Renal imaging:</b> Scintigraphic evaluation of renal parenchymal disorders in pediatric (including term neonates) and adult patients.</p></div>
<div class="block mst drugH1Div" id="F13255279"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F57529660"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F57529657"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F53623773"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Pregnancy status should be evaluated prior to use in women of reproductive potential (SNM 2010).</p>
<p style="text-indent:0em;margin-top:2em;">The manufacturer recommends elective studies be conducted during the first 10 days of the menstrual cycle in women of reproductive potential.</p></div>
<div class="block pri drugH1Div" id="F13214959"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Technetium Tc 99m can be detected in fetal tissue; the amount depends upon the specific formulation, route of administration, and stage of pregnancy (Adelstein 1999).</p>
<p style="text-indent:0em;margin-top:2em;">In general, the potential for a radiopharmaceutical to cause fetal harm depends on the dose absorbed by the fetus and the stage of pregnancy. High doses of radiopharmaceuticals used for therapeutic procedures are more likely to result in fetal harm. A medically required diagnostic procedure can usually be modified to decrease fetal risk. Elective diagnostic procedures should be delayed until after delivery (ACR-SPR 2018; Adelstein 1999; ICRP 2000; SNM 2010).</p></div>
<div class="block brc drugH1Div" id="F17916860"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Although an interruption of breastfeeding may not always be required (ABM [Mitchell 2019]), expressing and discarding breast milk for a period of 4 hours following technetium Tc 99m succimer for renal imaging may be considered (IAEA 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">During the period of breastfeeding interruption, the manufacturer recommends substituting formula for breast milk. Alternatively, women can pump and store breast milk prior to the procedure, which can be bottle-fed (Harding 1995).</p>
<p style="text-indent:-2em;margin-left:2em;">Elective diagnostic procedures should be delayed until breastfeeding has stopped (SNM 2010). Women who are breastfeeding and caring for individuals undergoing nuclear medicine procedures do not need any additional precautions (ABM [Mitchell 2019]).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion of technetium Tc 99m into colostrum is widely variable and information is limited; therefore, recommendations related to early breastfeeding cannot be made (Mountford 1989; Rubow 1994).</p></div>
<div class="block pha drugH1Div" id="F56670880"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Radioactive diagnostic agent which decays by isomeric transition to emit a photon that can be detected by imaging.</p></div>
<div class="block phk drugH1Div" id="F56670881"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 53% to 70%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life: Radioactive: 6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~16% within 2 hours).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23777112"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Renocis</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Renocis</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Technefit 99mtc</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-10331526">
<a name="10331526"></a>Adelstein SJ. Administered Radionuclides in Pregnancy. <i>Teratology</i>. 1999;59(4):236-239.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-succimer-drug-information/abstract-text/10331526/pubmed" id="10331526" target="_blank">10331526</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American College of Radiology (ACR), Society for Pediatric Radiology (SPR). ACR-SPR practice parameter for the performance of renal scintigraphy. https://www.acr.org/-/media/ACR/Files/Practice-Parameters/RenalScint.pdf. Revised 2017. Accessed February 24, 2020.</div>
</li>
<li>
<div class="reference">
                  American College of Radiology (ACR), Society for Pediatric Radiology (SPR). ACR–SPR practice parameter for imaging pregnant or potentially pregnant adolescents and women with ionizing radiation (resolution 39). Revised 2018. https://www.acr.org/-/media/ACR/Files/Practice-Parameters/Pregnant-Pts.pdf?la=en. Accessed February 24, 2020.</div>
</li>
<li>
<div class="reference">
                  Harding LK, Bossuyt S, Pellet C, et al. Recommendations for Nuclear Medicine Physicians Regarding Breastfeeding Mothers. <i>Eur J Nucl Med</i>. 1995;22(5)BP17.</div>
</li>
<li>
<div class="reference">
                  International Atomic Energy Agency. <i>IAEA Safety Standards for Protecting People and the Environment: Radiation Protection and Safety in Medical Uses of Ionizing Radiation. Specific Safety Guide No. SSG-46</i>. IAEA; 2018. https://www​.iaea.org​/publications/11102/radiation-protection-and-safety-in-medical-uses-of-ionizing-radiation.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11108925">
<a name="11108925"></a>International Commission on Radiological Protection (ICRP). Pregnancy and Medical Radiation. <i>Ann ICRP</i>. 2000;30(1):iii-viii, 1-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-succimer-drug-information/abstract-text/11108925/pubmed" id="11108925" target="_blank">11108925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31107104">
<a name="31107104"></a>Mitchell KB, Fleming MM, Anderson PO, Giesbrandt JG; Academy of Breastfeeding Medicine. ABM Clinical Protocol #31: radiology and nuclear medicine studies in lactating women. <i>Breastfeed Med</i>. 2019;14(5):290‐294. doi:10.1089/bfm.2019.29128.kbm<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-succimer-drug-information/abstract-text/31107104/pubmed" id="31107104" target="_blank">31107104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2645546">
<a name="2645546"></a>Mountford PJ, Coakley AJ. A Review of the Secretion of Radioactivity in Human Breast Milk: Data, Quantitative Analysis and Recommendations. <i>Nucl Med Commun</i>. 1989;10(1):15-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-succimer-drug-information/abstract-text/2645546/pubmed" id="2645546" target="_blank">2645546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2645546">
<a name="2645546"></a>Nephroscan (technetium tc 99m succimer) [prescribing information]. Braintree, MA: Theragnostics Inc; February 2022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-succimer-drug-information/abstract-text/2645546/pubmed" id="2645546" target="_blank">2645546</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Society of Nuclear medicine (SNM). Society of Nuclear Medicine procedure guideline for general imaging. Version 6.0. Revised 2010. http://s3.amazonaws.com/rdcms-snmmi/files/production/public/docs/General_Imaging_Version_6.0.pdf. Accessed July 22, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8162938">
<a name="8162938"></a>Rubow S, Klopper J, Wasserman H, et al. The Excretion of Radiopharmaceuticals in Human Breast Milk: Additional Data and Dosimetry. <i>Eur J Nucl Med</i>. 1994;21(2):144-153.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-succimer-drug-information/abstract-text/8162938/pubmed" id="8162938" target="_blank">8162938</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16817 Version 83.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
